CN118302526A - 一种dsRNA、其制备方法及应用 - Google Patents

一种dsRNA、其制备方法及应用 Download PDF

Info

Publication number
CN118302526A
CN118302526A CN202280076303.4A CN202280076303A CN118302526A CN 118302526 A CN118302526 A CN 118302526A CN 202280076303 A CN202280076303 A CN 202280076303A CN 118302526 A CN118302526 A CN 118302526A
Authority
CN
China
Prior art keywords
seq
nucleotide
dsrna
antisense strand
sense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280076303.4A
Other languages
English (en)
Chinese (zh)
Inventor
李云飞
张瑱
侯哲
耿俊
张建羽
周雅琴
黄龙飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Tuojie Biomedical Technology Co ltd
Original Assignee
Shanghai Tuojie Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Tuojie Biomedical Technology Co ltd filed Critical Shanghai Tuojie Biomedical Technology Co ltd
Publication of CN118302526A publication Critical patent/CN118302526A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280076303.4A 2021-12-16 2022-12-16 一种dsRNA、其制备方法及应用 Pending CN118302526A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021115427974 2021-12-16
CN202111542797 2021-12-16
PCT/CN2022/139488 WO2023109938A1 (zh) 2021-12-16 2022-12-16 一种dsRNA、其制备方法及应用

Publications (1)

Publication Number Publication Date
CN118302526A true CN118302526A (zh) 2024-07-05

Family

ID=86774893

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280076303.4A Pending CN118302526A (zh) 2021-12-16 2022-12-16 一种dsRNA、其制备方法及应用

Country Status (6)

Country Link
JP (1) JP2025500860A (https=)
KR (1) KR20240116537A (https=)
CN (1) CN118302526A (https=)
CA (1) CA3240651A1 (https=)
TW (1) TW202334425A (https=)
WO (1) WO2023109938A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024125636A1 (zh) * 2022-12-16 2024-06-20 上海拓界生物医药科技有限公司 Toll样受体调节剂与dsRNA的联合治疗
CN119816597A (zh) * 2023-08-10 2025-04-11 石药集团中奇制药技术（石家庄）有限公司 一种抑制HBV基因表达的dsRNA分子及其应用
CN116854754B (zh) 2023-09-01 2023-12-12 北京悦康科创医药科技股份有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
CN118638166B (zh) 2024-08-15 2024-12-17 北京悦康科创医药科技股份有限公司 含有三氮唑结构的GalNAc化合物及其寡核苷酸缀合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101773551B1 (ko) * 2008-10-15 2017-08-31 아이오니스 파마수티컬즈, 인코포레이티드 인자 １１ 발현의 조정
EA024762B9 (ru) * 2011-06-30 2017-04-28 Эрроухэд Рисерч Корпорейшн Композиции и способы ингибирования экспрессии генов вируса гепатита в
EP3719127A4 (en) * 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
CN111378655B (zh) * 2018-12-28 2024-03-19 苏州瑞博生物技术股份有限公司 抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途
AU2020280439B2 (en) * 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
KR20220011689A (ko) * 2019-05-22 2022-01-28 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도

Also Published As

Publication number Publication date
CA3240651A1 (en) 2023-06-22
KR20240116537A (ko) 2024-07-29
WO2023109938A1 (zh) 2023-06-22
TW202334425A (zh) 2023-09-01
JP2025500860A (ja) 2025-01-15

Similar Documents

Publication Publication Date Title
JP7849353B2 (ja) オフターゲット活性が低減された修飾ｓｉＲＮＡ
TW202229549A (zh) 抑制凝血因子ｘｉ表達的ｓｉｒｎａ、組成物及其醫藥用途
CN118302526A (zh) 一种dsRNA、其制备方法及应用
CN118541482A (zh) 一种dsRNA、其制备方法及应用
EP4328310A1 (en) Sirna targeting 17b-hydroxysteroid dehydrogenase type 13 and sirna conjugate
WO2023208023A1 (zh) 氘代化学修饰和包含其的寡核苷酸
TW202302851A (zh) Ｂ型肝炎病毒ｓｉＲＮＡ和ｓｉＲＮＡ綴合物
CN118339294A (zh) 一种dsRNA、其制备方法及应用
JP2024541713A (ja) アンジオテンシノーゲンを標的とするｓｉＲＮＡ及びその医薬的使用
CN118525092A (zh) 一种dsRNA、其应用及制备方法
CN118591628A (zh) 一种dsRNA、其应用及制备方法
RU2849194C1 (ru) МОДИФИЦИРОВАННАЯ миРНК С ПОНИЖЕННОЙ НЕЦЕЛЕВОЙ АКТИВНОСТЬЮ
EA052687B1 (ru) дцРНК, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ЕЕ ПРИМЕНЕНИЕ
WO2025130862A1 (zh) 一种新型的双链siRNA、其缀合物及其用途
CN119876130A (zh) 一种新型的双链siRNA、其缀合物及其用途
CN121495925A (zh) 一种靶向AGT的双链siRNA、其缀合物及其用途
CN120272473A (zh) 一种抑制淀粉样前体蛋白APP mRNA表达的siRNA、其缀合物和药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40113479

Country of ref document: HK